Publications

ZFTA-RELA ependymomas make itaconate to epigenetically drive fusion expression.

Authors: SK Natarajan, J Lum, JH Skeans, M Nenwani, S Eyunni, M Mota, JM Bayliss, A ...

E-pub date: 4 Feb 2026

Journal name: Nature

ApCAFs: spatial niches and therapeutic insights across cancers.

Authors: W Li, G Nsubuga, G Biffi

E-pub date: 1 Feb 2026

Journal name: Trends Cancer

Treatment resistance to platinum-based chemotherapy in lung and ovarian cancer is driven by a targetable TGFβ senescent secretome.

Authors:

E-pub date: 1 Feb 2026

Journal name: Nat Aging

Loss of CTLH component MAEA impairs DNA repair and replication and leads to developmental delay.

Authors: SH Hough, SS Jhujh, SW Awwad, OE Lewis, S Lam, JC Thomas, T Mosler, A Bader...

E-pub date: 1 Feb 2026

Journal name: EMBO Mol Med

MDC1 counteracts replication fork reversal and mediates chemosensitivity in BRCA1/2-deficient tumors.

Authors: H Dogan, M Liptay, JS Barbosa, E Gogola, AA Duarte, JA Schmid, I Klebic, M ...

E-pub date: 1 Feb 2026

Journal name: Oncogene

Author Correction: PHGDH heterogeneity potentiates cancer cell dissemination and metastasis.

Authors: M Rossi, P Altea-Manzano, M Demicco, G Doglioni, L Bornes, M Fukano, A Vand...

E-pub date: 1 Feb 2026

Journal name: Nature

Childhood brain tumors instruct cranial hematopoiesis and immunotolerance.

Authors: E Cooper, DA Posner, CYC Lee, L Hu, S Bonner, JT Taylor, O Baldwin, R Jimen...

E-pub date: 1 Feb 2026

Journal name: Nat Genet

ICON8B: GCIG phase III randomised trial comparing first-line weekly dose-dense chemotherapy + bevacizumab to three-weekly chemotherapy + bevacizumab in high-risk stage III-IV epithelial ovarian cancer: final overall survival (OS) analysis

Authors: A Clamp, I Mcneish, D Radice, R Lord, A Michael, A Cook, R Agarwal, A Walth...

E-pub date: 1 Feb 2026

Journal name: International Journal of Gynecological Cancer

Filters

Research Groups

Core Facilities

Start date

End date

ZFTA-RELA ependymomas make itaconate to epigenetically drive fusion expression.

ApCAFs: spatial niches and therapeutic insights across cancers.

Treatment resistance to platinum-based chemotherapy in lung and ovarian cancer is driven by a targetable TGFβ senescent secretome.

Loss of CTLH component MAEA impairs DNA repair and replication and leads to developmental delay.

MDC1 counteracts replication fork reversal and mediates chemosensitivity in BRCA1/2-deficient tumors.

Author Correction: PHGDH heterogeneity potentiates cancer cell dissemination and metastasis.

Childhood brain tumors instruct cranial hematopoiesis and immunotolerance.

ICON8B: GCIG phase III randomised trial comparing first-line weekly dose-dense chemotherapy + bevacizumab to three-weekly chemotherapy + bevacizumab in high-risk stage III-IV epithelial ovarian cancer: final overall survival (OS) analysis

Themes

Filters

Research Groups

Core Facilities

Start date

End date

ZFTA-RELA ependymomas make itaconate to epigenetically drive fusion expression.

ApCAFs: spatial niches and therapeutic insights across cancers.

Treatment resistance to platinum-based chemotherapy in lung and ovarian cancer is driven by a targetable TGFβ senescent secretome.

Loss of CTLH component MAEA impairs DNA repair and replication and leads to developmental delay.

MDC1 counteracts replication fork reversal and mediates chemosensitivity in BRCA1/2-deficient tumors.

Author Correction: PHGDH heterogeneity potentiates cancer cell dissemination and metastasis.

Childhood brain tumors instruct cranial hematopoiesis and immunotolerance.

ICON8B: GCIG phase III randomised trial comparing first-line weekly dose-dense chemotherapy + bevacizumab to three-weekly chemotherapy + bevacizumab in high-risk stage III-IV epithelial ovarian cancer: final overall survival (OS) analysis